ArticleClinical pharmacology and therapeutics2013
Using genetics to enable studies on the prevention of Alzheimer's disease.
Article in Clinical pharmacology and therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed.
- Article
- Navigating the treatment landscape of Alzheimer's disease: Current strategies and future directions.Ibrain · 2025Review
- Factors Influencing Alzheimer's Disease Risk: Whether and How They are Related to the APOE Genotype.Neuroscience bulletin · 2022Review
- Definitive roles of TOMM40-APOE-APOC1 variants in the Alzheimer's risk.Neurobiology of aging · 2022Article
- Short structural variants as informative genetic markers for ALS disease risk and progression.BMC medicine · 2022Article
- The role of structural variations in Alzheimer's disease and other neurodegenerative diseases.Frontiers in aging neuroscience · 2022Review
- Protective association of the ε2/ε3 heterozygote with Alzheimer's disease is strengthened by TOMM40-APOE variants in men.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021Article
- Article
- Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues.Schizophrenia research. Cognition · 2019Review
- The TOMMORROW study: Design of an Alzheimer's disease delay-of-onset clinical trial.Alzheimer's & dementia (New York, N. Y.) · 2019Article
- Biothiols and oxidative stress markers and polymorphisms ofOncotarget · 2018Article
- The effects of the TOMM40 poly-T alleles on Alzheimer's disease phenotypes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2018Review
- TOMMORROW neuropsychological battery: German language validation and normative study.Alzheimer's & dementia (New York, N. Y.) · 2018Article
- Neuropathologic features of TOMM40 '523 variant on late-life cognitive decline.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Article
- The biological foundation of the genetic association of TOMM40 with late-onset Alzheimer's disease.Biochimica et biophysica acta. Molecular basis of disease · 2017Article
- Characterization ofAlzheimer's & dementia (New York, N. Y.) · 2017Article
- The Alu neurodegeneration hypothesis: A primate-specific mechanism for neuronal transcription noise, mitochondrial dysfunction, and manifestation of neurodegenerative disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2017Article
- Proteomic differences in brain vessels of Alzheimer's disease mice: Normalization by PPARγ agonist pioglitazone.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2017Article
- Article
- APOE ε4-TOMM40 '523 haplotypes and the risk of Alzheimer's disease in older Caucasian and African Americans.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Curing Alzheimer's disease (AD) remains an elusive goal; indeed, it may even prove to be impossible, given the nature of the disease. Although modulating disease progression is an attractive target and will alleviate the burden of the most severe stages, this strategy will not reduce the prevalence of the disease itself. Preventing or (as described in this article) delaying the onset of cognitive impairment and AD will provide the greatest benefit to individuals and society by pushing the onset of disease into the later years of life. Because of the high variability in the age of onset of the disease, AD prevention studies that do not stratify participants by age-dependent disease risk will be operationally challenging, being large in size and of long duration. We present a composite genetic biomarker to stratify disease risk so as to facilitate clinical studies in high-risk populations. In addition, we discuss the rationale for the use of pioglitazone to delay the onset of AD in individuals at high risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.